AI-based oncology therapeutics developer Frontier Medicines has raised USD 20 million in extended Series C funding, bringing the total proceeds of the round to USD 100 million. Investors such as Deep Track Capital and ArrowMark Partners participated in the funding round.
The additional funds will be invested in accelerating the development of FMC-376 and several ongoing pipeline programs, with the goal of submitting one Investigational New Drug (IND) per year. Along with the funding, the company has also announced the appointment of Gerardo Ubaghs as the CFO of the company.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.